vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Insulet Corporation is the larger business by last-quarter revenue ($761.7M vs $708.5M, roughly 1.1× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 12.0%, a 7.1% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (33.9% vs 32.0%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $89.5M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (24.9% CAGR vs 17.7%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
MEDP vs PODD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $761.7M |
| Net Profit | $135.1M | $91.1M |
| Gross Margin | — | 69.5% |
| Operating Margin | 21.6% | 16.0% |
| Net Margin | 19.1% | 12.0% |
| Revenue YoY | 32.0% | 33.9% |
| Net Profit YoY | 15.5% | 157.3% |
| EPS (diluted) | $4.65 | $1.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $761.7M | ||
| Q4 25 | $708.5M | $783.7M | ||
| Q3 25 | $659.9M | $706.3M | ||
| Q2 25 | $603.3M | $649.1M | ||
| Q1 25 | $558.6M | $569.0M | ||
| Q4 24 | $536.6M | $597.5M | ||
| Q3 24 | $533.3M | $543.9M | ||
| Q2 24 | $528.1M | $488.5M |
| Q1 26 | — | $91.1M | ||
| Q4 25 | $135.1M | $101.6M | ||
| Q3 25 | $111.1M | $87.6M | ||
| Q2 25 | $90.3M | $22.5M | ||
| Q1 25 | $114.6M | $35.4M | ||
| Q4 24 | $117.0M | $100.7M | ||
| Q3 24 | $96.4M | $77.5M | ||
| Q2 24 | $88.4M | $188.6M |
| Q1 26 | — | 69.5% | ||
| Q4 25 | — | 72.6% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 69.7% | ||
| Q1 25 | — | 71.9% | ||
| Q4 24 | — | 72.1% | ||
| Q3 24 | — | 69.3% | ||
| Q2 24 | — | 67.7% |
| Q1 26 | — | 16.0% | ||
| Q4 25 | 21.6% | 18.7% | ||
| Q3 25 | 21.5% | 16.7% | ||
| Q2 25 | 20.9% | 18.7% | ||
| Q1 25 | 20.3% | 15.6% | ||
| Q4 24 | 23.4% | 18.3% | ||
| Q3 24 | 21.1% | 16.2% | ||
| Q2 24 | 19.9% | 11.2% |
| Q1 26 | — | 12.0% | ||
| Q4 25 | 19.1% | 13.0% | ||
| Q3 25 | 16.8% | 12.4% | ||
| Q2 25 | 15.0% | 3.5% | ||
| Q1 25 | 20.5% | 6.2% | ||
| Q4 24 | 21.8% | 16.9% | ||
| Q3 24 | 18.1% | 14.2% | ||
| Q2 24 | 16.7% | 38.6% |
| Q1 26 | — | $1.30 | ||
| Q4 25 | $4.65 | $1.42 | ||
| Q3 25 | $3.86 | $1.24 | ||
| Q2 25 | $3.10 | $0.32 | ||
| Q1 25 | $3.67 | $0.50 | ||
| Q4 24 | $3.67 | $1.38 | ||
| Q3 24 | $3.01 | $1.08 | ||
| Q2 24 | $2.75 | $2.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $480.4M |
| Total DebtLower is stronger | — | $18.6M |
| Stockholders' EquityBook value | $459.1M | $1.3B |
| Total Assets | $2.0B | $3.0B |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $480.4M | ||
| Q4 25 | $497.0M | — | ||
| Q3 25 | $285.4M | — | ||
| Q2 25 | $46.3M | — | ||
| Q1 25 | $441.4M | — | ||
| Q4 24 | $669.4M | — | ||
| Q3 24 | $656.9M | — | ||
| Q2 24 | $510.9M | — |
| Q1 26 | — | $18.6M | ||
| Q4 25 | — | $930.8M | ||
| Q3 25 | — | $934.9M | ||
| Q2 25 | — | $939.0M | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $459.1M | $1.5B | ||
| Q3 25 | $293.6M | $1.4B | ||
| Q2 25 | $172.4M | $1.5B | ||
| Q1 25 | $593.6M | $1.3B | ||
| Q4 24 | $825.5M | $1.2B | ||
| Q3 24 | $881.4M | $1.1B | ||
| Q2 24 | $763.6M | $998.4M |
| Q1 26 | — | $3.0B | ||
| Q4 25 | $2.0B | $3.2B | ||
| Q3 25 | $1.8B | $3.0B | ||
| Q2 25 | $1.6B | $3.5B | ||
| Q1 25 | $1.9B | $3.5B | ||
| Q4 24 | $2.1B | $3.1B | ||
| Q3 24 | $2.1B | $3.0B | ||
| Q2 24 | $1.9B | $2.9B |
| Q1 26 | — | 0.01× | ||
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.68× | ||
| Q2 25 | — | 0.64× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | $113.8M |
| Free Cash FlowOCF − Capex | $188.1M | $89.5M |
| FCF MarginFCF / Revenue | 26.6% | 11.8% |
| Capex IntensityCapex / Revenue | 0.6% | 3.2% |
| Cash ConversionOCF / Net Profit | 1.43× | 1.25× |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | $415.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $113.8M | ||
| Q4 25 | $192.7M | $183.3M | ||
| Q3 25 | $246.2M | $125.7M | ||
| Q2 25 | $148.5M | $196.5M | ||
| Q1 25 | $125.8M | $63.8M | ||
| Q4 24 | $190.7M | $147.7M | ||
| Q3 24 | $149.1M | $98.5M | ||
| Q2 24 | $116.4M | $96.5M |
| Q1 26 | — | $89.5M | ||
| Q4 25 | $188.1M | $48.2M | ||
| Q3 25 | $235.5M | $100.1M | ||
| Q2 25 | $142.4M | $177.9M | ||
| Q1 25 | $115.8M | $51.5M | ||
| Q4 24 | $183.0M | $94.1M | ||
| Q3 24 | $138.5M | $71.8M | ||
| Q2 24 | $103.5M | $74.0M |
| Q1 26 | — | 11.8% | ||
| Q4 25 | 26.6% | 6.2% | ||
| Q3 25 | 35.7% | 14.2% | ||
| Q2 25 | 23.6% | 27.4% | ||
| Q1 25 | 20.7% | 9.1% | ||
| Q4 24 | 34.1% | 15.7% | ||
| Q3 24 | 26.0% | 13.2% | ||
| Q2 24 | 19.6% | 15.1% |
| Q1 26 | — | 3.2% | ||
| Q4 25 | 0.6% | 17.2% | ||
| Q3 25 | 1.6% | 3.6% | ||
| Q2 25 | 1.0% | 2.9% | ||
| Q1 25 | 1.8% | 2.2% | ||
| Q4 24 | 1.4% | 9.0% | ||
| Q3 24 | 2.0% | 4.9% | ||
| Q2 24 | 2.4% | 4.6% |
| Q1 26 | — | 1.25× | ||
| Q4 25 | 1.43× | 1.80× | ||
| Q3 25 | 2.22× | 1.43× | ||
| Q2 25 | 1.65× | 8.73× | ||
| Q1 25 | 1.10× | 1.80× | ||
| Q4 24 | 1.63× | 1.47× | ||
| Q3 24 | 1.55× | 1.27× | ||
| Q2 24 | 1.32× | 0.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
PODD
| Omnipod | $515.6M | 68% |
| International Omnipod | $242.9M | 32% |
| Drug Delivery | $3.3M | 0% |
